natgillin/translations-raw huggingface dataset:
Resistance analysis by week 144
Analiza odpornosti do 144. tedna
Resistance can also arise via the acquisition of betalactamases with significant carbapenem-hydrolysing activity (e.g.
Do odpornosti lahko pride tudi ob pripojitvi betalaktamaz z značilno karbapenemsko-hidrolizno aktivnostjo (npr.
resistance development (CYP450 enzyme
razvoj rezistence (indukcija CYP450).
Resistance development primarily occurs because of changes at the binding site associated with mutations of the ribosomal DNA genes.
Odpornost se pojavlja predvsem zaradi sprememb na mestu vezave, ki so povezane z mutacijami genov ribosomske DNK.
Resistance in CP-CML was defined as failure to achieve either a complete haematological response (by 3 months), a minor cytogenetic response (by 6 months), or a major cytogenetic response (by
Odpornost pri CP-KML je bila opredeljena kot nedoseganje celovitega hematološkega odgovora (po 3 mesecih), manjši citogenetski odgovor (po 6 mesecih) ali bistven citogenetski odgovor (po
Resistance in vitro and in vivo: (abacavir and lamivudine)
Odpornost in vitro in in vivo: (abakavir in lamivudin)
Resistance outcomes, including cross resistance to other NNRTIs, in patients receiving rilpivirine hydrochloride in combination with emtricitabine/tenofovir disoproxil fumarate in Phase III studies (C209 and C215 pooled data) and experiencing virological failure, are shown in Table 3 below.
Izidi rezistence, vključno z navzkrižno rezistenco na druge NNRTI, pri bolnikih, ki prejemajo rilpivirinijev klorid v kombinaciji z emtricitabinom/dizoproksiltenofovirijevim fumaratom v študijah faze III (združeni podatki C209 in C215), ki so doživeli virološki neuspeh, so navedene v preglednici 3 spodaj.
resistance protein/ABCG2) and
Antiaritmiki
resistance to atazanavir (see
odpornosti proti atazanavirju (glejte
Resistance to cephalosporins results from enzymatic inactivation (-lactamase production) or from other mechanisms.
Rezistenca na cefalosporine je rezultat encimske inaktivacije (proizvodnja β-laktamaze) ali drugih mehanizmov.
Resistance to cephalosporins results from enzymatic inactivation (-lactamase production), from reduced permeability by porin mutations or change in efflux, or by selection of low-affinity penicillin-binding proteins.
Rezistenca na cefalosporine je rezultat encimske inaktivacije (proizvodnja β-laktamaze), zmanjšane propustnosti zaradi mutacij ali sprememb izliva proteina porin ali zaradi izbire za vezavo penicilinov manj privlačnih proteinov.
Resistance to dalbavancin in Staphylococcus spp. and Enterococcus spp. is mediated by VanA, a genotype that results in modification of the target peptide in nascent cell wall.
Odpornost na dalbavancin pri Staphylococcus spp. in Enterococcus spp. je posredovana z VanA, genotipom, ki povzroči spremembo ciljnega peptida v nastajajoči celični steni.
Resistance to delamanid has occurred during treatment.
Med zdravljenjem se je pojavila odpornost na delamanid.
Resistance to efavirenz
odpornost na efavirenz
Resistance to efavirenz
Rezistenca na efavirenz
Resistance to emtricitabine/lamivudine
odpornost na emtricitabin/lamivudin
Resistance to emtricitabine/lamivudine
Rezistenca na emtricitabin/lamivudin
Resistance to fluoroquinolones has been reported to arise from five sources, (i) point mutations in the genes encoding for DNA gyrase and/or topoisomerase IV leading to alterations of the respective enzyme, (ii) alterations of drug permeability in Gram-negative bacteria, (iii) efflux mechanisms, (iv) plasmid mediated resistance and (v) gyrase protecting proteins.
Na razvoj odpornosti proti fluorokinolonom vpliva pet vzrokov: (i) točkovna mutacija v genih za kodiranje encima DNK giraze in/ali topoizomerazo IV kar vodi k spremembi ustreznega encima, (ii) spremembe, ki so povezane s prepustnostjo gramnegativnih bakterij za zdravilo, (iii) mehanizem efluksa, (iv) mutacija plazmidnega gena in (v) proteini za zaščito DNK giraze.
Resistance to fluoroquinolones occurs by chromosomal mutation with three mechanisms: Decrease of the bacterial wall permeability, expression of efflux pump, or mutation of enzymes responsible for the molecule’s binding site.
Do rezistence na fluorkinolone pride zaradi treh mehanizmov, ki sodelujejo pri mutaciji kromosomov: zmanjšanje prepustnosti bakterijske stene, delovanja efflux črpalke in pa mutacije encima odgovornega za vezavo molekul.
Resistance to levofloxacin is most often acquired through a stepwise process by target site mutations in DNA gyrase and topoisomerase IV.
Odpornost proti levofloksacinu se najpogosteje razvije v stopenjskem procesu in sicer z mutacijami ciljnih mest v DNA girazi in v topoizomerazi IV.
Resistance to lopinavir, defined as the presence of any primary or active site mutations in protease (see above), was observed in 0/51 (0%) patients.
Odpornost proti lopinavirju, definirana kot prisotnost katerekoli primarne mutacije ali mutacije aktivnega mesta v proteazi (glejte zgoraj), je bila opažena pri 0/51 (0%) bolnikih.
Resistance to macrolides can develop by mutations in genes encoding ribosomal RNA (rRNA) or some ribosomal proteins; by enzymatic modification (methylation) of the 23S rRNA target site, generally giving rise to cross-resistance with lincosamides and group B streptogramins (MLSB
Rezistenca na makrolide se lahko razvije zaradi mutacij genov, ki kodirajo ribosomalno RNK (rRNK) oziroma nekaterih ribosomalnih proteinov; z encimsko modifikacijo (metilacijo) 23S rRNK tarčnega mesta, kar običajno povzroči povečanje navzkrižne rezistence z likozamidi in skupino B streptogramnov (MLSB rezistenca); z encimsko inaktivacijo ali pa z izločanjem makrolidov.
Resistance to macrolides generally results from three mechanisms: (1) the alteration of the ribosomal target site (methylation), often referred to as MLSB resistance as it affects macrolides, lincosamides and group B streptogramins, (2) the utilisation of active efflux mechanism; (3) the production of inactivating enzymes.
Rezistenca na makrolide je na splošno posledica treh mehanizmov: (1) spremembe ribosomskega ciljnega mesta (metilacija), ki jo pogosto označujejo kot rezistenco na MLSB, ker deluje na makrolide, linkozamide in na skupino B streptograminov, (2) izkoriščanja aktivnega mehanizma iztekanja; (3) proizvodnje inaktivirajočih encimov.
Resistance to macrolides generally results from three mechanisms: (1) the alteration of the ribosomal target site (methylation), often referred to as MLSB resistance as it affects macrolides, lincosamides and group B streptogramins; (2) the utilisation of active efflux mechanism; (3) the production of inactivating enzymes.
Rezistenca na makrolide je na splošno posledica treh mehanizmov: (1) spremembe ribosomskega ciljnega mesta (metilacija), ki jo pogosto označujejo kot rezistenco na MLSB, ker deluje na makrolide, linkozamide in na skupino B streptograminov, (2) izkoriščanje aktivnega mehanizma iztekanja; (3) proizvodnja inaktivirajočih encimov.
resistance to maraviroc.
odpornosti proti maraviroku.
Resistance to nelfinavir, defined as the presence of the D30N or L90M mutation in protease, was observed in 41/96 (43%) patients.
Odpornost proti nelfinavirju, definirana kot prisotnost D30N ali L90M mutacij v proteazi, je bila opažena pri 41/96 (43%) bolnikih.
Resistance to paritaprevir and ombitasvir conferred by variants in NS3 and NS5A respectively, selected in cell culture or identified in Phase 2b and 3 clinical trials were phenotypically characterised in the appropriate genotype 1a or 1b replicons.
Odpornost proti paritaprevirju in ombitasvirju, povezana z variantami NS3 in NS5A, selekcioniranih v celičnih kulturah ali identificiranih v kliničnih preskušanjih faze 2b in 3, so fenotipsko opredelili v ustreznih replikonih genotipa 1a ali 1b.
Resistance to rilpivirine
Rezistenca na rilpivirin
Resistance to rilpivirine was determined as a fold change in EC50 value (FC) above the biological cut-off (BCO) of the assay.
Rezistenco na rilpivirin so določili kot spremembo stopnje (FC – fold change) v vrednosti EC50 nad biološko zgornjo mejo (BCO – biological cut-off) testa občutljivosti.
Resistance to rilpivirine2 Cross resistance3 to etravirine efavirenz nevirapine
Rezistenca na rilpivirin1 Navzkrižna rezistenca2 na etravirin efavirenz nevirapin
Resistance to tylvalosin by Mycoplasma hyopneumoniae and Lawsonia intracellularis has not been reported or found in the field to date.
O rezistenci Mycoplasma hyopneumoniae in Lawsonia intracellularis na tilvalozin ni poročil, ali pa ta ni bila ugotovljena.
Resistance# to emtricitabine/lamivudine
odpornost# na emtricitabin/lamivudin
resistance.
odpornostjo proti
Resistance: HIV-1 resistance to emtricitabine develops as the result of changes at codon 184 causing the methionine to be changed to a valine (an isoleucine intermediate has also been observed) of the HIV reverse transcriptase.
Rezistenca: Rezistenca virusa HIV-1 na emtricitabin se razvije kot posledica sprememb v kodonu 184 HIV reverzne transkriptaze, ki povzroči spremembo metionina v valin (opažen je bil tudi izoleucinski intermediat).
Resistance: No HBV mutations associated with tenofovir disoproxil fumarate resistance have been identified (see Clinical efficacy and safety).
Rezistenca: Mutacij virusa HBV, povezanih z rezistenco na dizoproksiltenofovirijev fumarat, niso odkrili (glejte razdelek Klinična učinkovitost in varnost).
Resistance: Viral escape from nelfinavir can occur via viral protease mutations at amino acid positions 30, 88 and 90.
Odpornost: virus se lahko izogne učinku nelfinavirja s pomočjo mutacij virusne proteaze na aminokislinskih mestih 30, 88 in 90.
Resistant
rezistenca
Resistant (n=109)
rezistenca (n=109)
Resistant (n=226)
rezistenca (n=226)
Resistant (R>)
Odporni (R >)
Resistant to FPV/RTV
Odporni proti FPV/RTV
Resistant to Prior TKI Therapy a *, n (%)
Odpornost na predhodno zdravljenje s TKIa*, n (%)
Reslizumab clearance is approximately 7 mL/hour.
Očistek reslizumaba je približno 7 ml/uro.
Reslizumab produced significant reductions in asthma exacerbations relative to placebo in the refractory population (59%) and non-refractory population (49%).
Reslizumab je povzročil pomembno zmanjšanje poslabšanj astme glede na placebo pri neodzivni populaciji (59 %) in odzivni populaciji (49 %).
Resocortol butyrate 1 mg/g
Resokortol butirat 1 mg/g
Resocortol butyrate 1 mg/g
Resokortol butirat, 1 mg/g
Resocortol butyrate 1mg/g
Resokortol butirat, 1 mg/g
Resocortol butyrate: 1mg/g
Resokortol butirat: 1 mg/g
Resolor 1 mg film-coated tablets are white to off-white round shaped tablets marked “PRU 1” on one side.
Filmsko obložene 1 mg tablete Resolor so bele do belkaste okrogle tablete z oznako „PRU 1“ na eni strani.
Resolor can be taken with or without food and drinks, at any time of the day.
Zdravilo Resolor lahko vzamete s hrano in pijačo ali brez nje ob katerem koli času dneva.
Resolor is not recommended during pregnancy.
Zdravilo Resolor se ne priporoča v nosečnosti.
Resolor with food and drink
Zdravilo Resolor skupaj s hrano in pijačo
Resolution occurred in 116 patients (92.8%) with a median time to resolution of 5.0 weeks (range: 0.1-53.1).
Do izboljšanja je prišlo pri 116 bolnikih (92,8 %), mediani čas do izboljšanja pa je znašal 5,0 tedna (razpon: 0,1-53,1).
Resolution occurred in 17 patients (89.5%) with a median time to resolution of 1.9 weeks (range: 0.4- 42.6+).
Do izboljšanja je prišlo pri 17 bolnikih (89,5 %), mediani čas do izboljšanja pa je znašal 1,9 tedna (razpon: 0,4-42,6+).
Resolution occurred in 184 patients (90.6%) with a median time to resolution of 3.0 weeks (range: 0.1-78.7+).
Do izboljšanja je prišlo pri 184 bolnikih (90,6 %), mediani čas do izboljšanja pa je znašal 3,0 tedna (razpon: 0,1-78,7+).
Resolution occurred in 19 patients (83%) with a median time to resolution of 2.0 weeks (range: 0.1-31.0).
Do izboljšanja je prišlo pri 19 bolnikih (83 %), mediani čas do izboljšanja pa je znašal 2,0 tedna (razpon: 0,1-31,0).
Resolution occurred in 192 patients (67.6%) with a median time to resolution of 10.4 weeks (range: 0.1-74.0+).
Do izboljšanja je prišlo pri 192 bolnikih (67,6 %), mediani čas do izboljšanja pa je znašal 10,4 tedna (razpon: 0,1-74,0+).
Resolution occurred in 207 patients (89%) with a median time to resolution of 2.1 weeks (range: 0.1-88.3+).
Do izboljšanja je prišlo pri 207 bolnikih (89 %), mediani čas do izboljšanja pa je znašal 2,1 tedna (razpon: 0,1-88,3+).
Resolution occurred in 47 patients (84%) with a median time to resolution of 5.3 weeks (range: 0.6-53.1+); + denotes a censored observation.
Do izboljšanja je prišlo pri 47 bolnikih (84 %), mediani čas do izboljšanja pa je znašal 5,3 tedna (razpon: 0,6-53,1+); + označuje krnjene podatke.
Resolution occurred in 6 patients (50%) with a median time to resolution of 20.6 weeks (0.4-47.6+); + denotes a censored observation.
Do izboljšanja je prišlo pri 6 bolnikih (50 %), mediani čas do izboljšanja pa je znašal 20,6 tedna (0,4-47,6+); + označuje krnjene podatke.
Resolution occurred in 74 patients (45%) with a median time to resolution of 66.6 weeks (0.4-96.1+).
Do izboljšanja je prišlo pri 74 bolnikih (45 %), mediani čas do izboljšanja pa je znašal 66,6 tedna (0,4-96,1+).
Resolution occurred in 95 patients (79%) with a median time to resolution of 5.1 weeks (range: 0.1-82.6+).
Do izboljšanja je prišlo pri 95 bolnikih (79 %), mediani čas do izboljšanja pa je znašal 5,1 tedna (razpon: 0,1-82,6+).
Resolution occurred in all 13 patients with a median time to resolution of 3.9 weeks (range: 0.6-13.4).
Do izboljšanja je prišlo pri vseh 13 bolnikih, mediani čas do izboljšanja pa je znašal 3,9 tedna (razpon: 0,6-13,4).
Resolves to <480 ms or baseline
Izboljša se na <480 ms ali na izhodiščno stanje.
Resolves to <480 ms or baseline
izboljša se na <480 ms ali v izhodišče
Resolves to Grade 0-1 or baseline.
izboljša se na stopnjo 0-1 ali v izhodišče
Resolves to Grade 0-1.
izboljša se na stopnjo 0-1
Resolves to less than 2 gm / 24 hours.
izboljša se na manj kot 2 g / 24 ur
Resolves to less than 2 gm / 24 hours.
Izboljša se na manj kot 2 g / 24 ur.
Resorption bone increased*
osteoliza* povečana resorpcija kosti
Resources for the management of anaphylaxis or serious reactions should be available.
Na voljo morajo biti sredstva za obravnavo anafilakse in resnih reakcij.
Resources for the management of hypersensitivity and/or anaphylactic reactions should be available.
Na voljo morajo biti sredstva za ukrepanje v primeru preobčutljivosti in/ali anafilaktičnih reakcij.
respect to efficacy and
učinkovitost in varnost niso
respectively ).
0,0 %).
respectively.
20,5 % of radioaktivne vrednosti AUC.
respectively.The percent reduction at 12 weeks for sildenafil 20 mg, 40 mg and 80 mg TID in PVR (11.2 %, 12.9 %, 23.3 %) was proportionally greater than the reduction in systemic vascular resistance (SVR) (7.2 %, 5.9 %, 14.4 %).
Odstotek znižanja pljučne žilne upornosti (11,2 % za 20 mg trikrat na dan, 12,9 % za 40 mg trikrat na dan in 23,3 % za 80 mg trikrat na dan) je bil po 12 tednih proporcionalno večji kot znižanje sistemske žilne upornosti (7,2 % za 20 mg trikrat na dan, 5,9 % za 40 mg trikrat na dan in 14,4 % za 80 mg trikrat na dan).
RESPIPORC FLU3 contains small amounts of a modified and then killed form of the pig’s influenza virus that causes lesions and illness.
Zdravilo RESPIPORC FLU3 vsebuje majhne količine modificirane in zatem inaktivirane oblike virusa prašičje gripe, ki povzroča lezije in bolezen.
RESPIPORC FLU3 suspension for injection for pigs
RESPIPORC FLU3 suspenzija za injiciranje za prašiče
Respiration abnormal, oropharyngeal pain, sinus congestion*, rhinorrhoea, pharyngeal erythema*
nenormalno dihanje, bolečina v ustih in žrelu, kongestija obnosnih votlin*, rinoreja, eritem žrela
respiratory
bolezen dihal, bolečina v
Respiratory
Bolezni dihal
respiratory
dihalna odpoved,
Respiratory -related death
Z dihali povezani smrtni izidi
Respiratory and cardiac symptoms such as bronchospasm, larynx and throat irritation, wheezing, laryngeal oedema and atrial fibrillation have also been reported (see section 4.4).
Poročali so tudi o respiratornih in srčnih simptomih, kot so bronhospazem, vnetje grla in žrela, sopenje, edem grla in atrijska fibrilacija (glejte poglavje 4.4).
Respiratory and CNS depression
Respiratorna depresija in depresija centralnega živčnega sistema
Respiratory arrest
respirat orni arest
Respiratory depression
bronhospazem respiratorna depresija
Respiratory depression
depresija dihanja
Respiratory depression may lead to respiratory acidosis and respiratory arrest (at sevoflurane concentrations of 2.0 MAC and above) in spontaneously breathing dogs.
Depresija dihanja lahko povzroči respiracijsko acidozo in zastoj dihanja (pri koncentracijah servoflurana 2,0 MAC in višjih) pri psih, ki spontano dihajo.
Respiratory depression Sleep apnoea syndrome
respiratorna depresija, sindrom spalne apneje
Respiratory depression, epistaxis, nasal ulcer, rhinorrhea
depresija dihanja, krvavitev iz nosu, nosna razjeda, rinoreja
respiratory disease, chest pain, dyspnoea, increased cough, rhinitis
bolezen dihal, bolečina v
respiratory disease, suicide or hospitalisation for suicide attempt, and new
dogodkov, novo odkritega raka, hospitalizacij zaradi vseh vzrokov,
Respiratory Diseases (Underlying Lung Disease)
Bolezni dihal (osnovne bolezni pljuč)
Respiratory disorder
bolezni dihal
Respiratory disorder
dihalne motnje
Respiratory disorder
motnje dihanja
Respiratory disorder
motnje pozornosti parestezije
respiratory disorder, oropharyngeal pain, cough, dysphonia
bolezni dihal, orofaringealne bolečine, kašelj, disfonija
Respiratory disorders
Bolezni dihal
respiratory disorders and inflammation (including asthma, shortness of breath, cough, blocked sinuses, pleurisy, or difficulty breathing)
obolenja in vnetja dihal (vključno z astmo, kratko sapo, kašljem, zamašenimi sinusi, vnetjem rebrne mrene ali oteženo dihanje)
Respiratory disorders Cough.
Bolezni dihal Kašelj
Respiratory disorders, including dyspnoea (21%), cough (18%) and tachypnoea (13%) were very commonly reported, and two patients with pre-existing asthma developed mild to moderate respiratory distress associated with MEPACT treatment in a phase II study.
Zelo pogosto so poročali o boleznih dihal, vključno z dispnejo (21 %), kašljem (18 %) in tahipnejo (13 %), pri dveh bolnikih s predhodno astmo pa se je razvila blaga do zmerna dihalna stiska, povezana z zdravljenjem z zdravilom MEPACT v študiji II. faze.
Respiratory disorders:
Motnje dihanja
Respiratory distress (including pneumonitis and pulmonary oedema)
Redki: dihalna stiska (tudi pnevmonitis in pljučni edem)
Respiratory distress (including pneumonitis and pulmonary oedema)
respiratorni distres (vključno s pljučnico in pljučnim edemom)
Respiratory distress (including pneumonitis and pulmonary oedema) h
dihalna stiska (vključno s pljučnico in pljučnim edemom) h
Respiratory distress, Dyspnoea
Organski sistem
Respiratory distress, dyspnoea, cough
težave z dihanjem, dispneja, kašelj
Respiratory distress, pulmonary oedema, pneumonitis
dihalna stiska, pljučni edem, pljučnica
Respiratory distress, wheezing, cough, rhinitis, nasal congestion, sneezing
dihalna stiska, zasoplost, kašelj, rinitis, zamašen nos, kihanje
respiratory distress9
dihalna stiska9
Respiratory domain of Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Revidirani vprašalnik za cistično fibrozo, poglavje Dihala (CFQ-R, Respiratory domain of Cystic Fibrosis Questionnaire - Revised)
Respiratory Domain Score at Week 24 (points)
24. tednu (točke)
Respiratory Drugs
Zdravila za zdravljenje dihal
Respiratory events
Dogodki na dihalih
Respiratory events
Respiracijski dogodki
Respiratory events (e.g., chest discomfort, dyspnoea, and respiration abnormal) were more common during initiation of lumacaftor/ivacaftor therapy.
Respiracijski dogodki (npr. neugodje v prsih, dispneja in nenormalno dihanje) so bili pogostejši med uvajanjem zdravljenja z lumakaftorjem/ivakaftorjem.
Respiratory events like dyspnoea and pulmonary oedema, particularly in association with concomitant administration of other medicinal products with tocolytic activity, like calcium antagonists and beta- mimetics, and/or in women with multiple pregnancy, have been reported post-marketing.
V obdobju po prihodu zdravila na trg so poročali o respiratornih zapletih, kot so dispneja in pljučni edem, še posebej v povezavi s sočasno uporabo drugih zdravil s tokolitičnim delovanjem, kot so antagonisti kalcijevih kanalčkov in beta-mimetiki, in/ali pri ženskah z večplodno nosečnostjo.
Respiratory events such as shortness of breath or chest tightness were seen in patients when starting Orkambi.
Pri bolnikih, ki začnejo jemati zdravilo Orkambi, so opazili dogodke v zvezi z dihanjem, na primer kratko sapo ali stiskanje v prsih.
Respiratory failure
diareja
respiratory failure
odpoved dihal
respiratory failure
odpoved dihanja
respiratory failure
odpoved dihanja,
Respiratory failure
respiratorna odpoved
Respiratory failure, Acute respiratory distress syndrome, Apnoea, Pneumothorax, Atelectasis, Pulmonary hypertension, Haemoptysis, Hyperventilation, Orthopnoea, Pneumonitis, Respiratory alkalosis, Tachypnoea, Pulmonary fibrosis, Bronchial disorder*, Hypocapnia*, Interstitial lung disease, Lung infiltration, Throat tightness, Dry throat, Increased upper airway secretion, Throat irritation, Upper-airway cough syndrome
respiratorna odpoved, sindrom akutne dihalne stiske, apneja, pnevmotoraks, atelektaza, pljučna hipertenzija, hemoptiza, hiperventilacija, ortopneja, pnevmonitis, respiratorna alkaloza, tahipneja, pljučna fibroza, bolezni bronhijev*, hipokapnija*, intersticijska bolezen pljuč, infiltracija pljuč, stiskanje v grlu, suho grlo, zvečana sekrecija iz zgornjih dihal, draženje žrela, sindrom kašlja zgornjih dihalnih poti (UACS - Upper-airway cough syndrome)
Respiratory failure, Acute respiratory distress syndrome, Apnoea, Pneumothorax, Atelectasis, Pulmonary hypertension, Haemoptysis, Hyperventilation, Orthopnoea, Pneumonitis, Respiratory alkalosis, Tachypnoea, Pulmonary fibrosis, Bronchial disorder*, Hypocapnia*, Interstitial lung disease, Lung infiltration, Throat tightness, Dry throat, Increased upper airway secretion, Throat irritation, Upper-airway cough syndrome
respiratorna odpoved, sindrom akutne dihalne stiske, apneja, pnevmotoraks, atelektaza, pljučna hipertenzija, hemoptiza, hiperventilacija, ortopneja, pnevmonitis, respiratorna alkaloza, tahipneja, pljučna fibroza, bolezni bronhijev*, hipokapnija*, intersticijska bolezen pljuč, infiltracija pljuč, stiskanje v grlu, suho grlo, zvečana sekrecija iz zgornjih dihal, draženje žrela, sindrom kašlja zgornjih dihalnih poti (UACS – Upper-airway cough syndrome)
respiratory failure, acute respiratory distress syndromeb, lung infiltration, pulmonary oedema, pneumonitis, allergic rhinitis
odpoved dihanja, sindrom akutne dihalne stiskeb, infiltracija pljuč, pljučni edem, pljučnica, alergijski rinitis
Respiratory failure, pneumonia aspiration
odpoved dihanja, aspiracijska pljučnica
respiratory failure.
odpoved dihanja
respiratory failure4,
mediastinalne
respiratory failure4,
odpoved dihal4
respiratory infection
okužba dihal
respiratory infection numbness
okužba dihal odrevenelost
respiratory infections – such as of the nose, sinuses or throat
okužbe dihal – nosu, sinusov, žrela ali grla
Respiratory infections, bronchitis, coughing with phlegm, flu like illness
okužbe dihal, bronhitis, produktiven kašelj, gripi podobna bolezen
Respiratory insufficiency: treat with artificial respiration
respiratorno insuficienco z umetnim dihanjem;
respiratory problems, i.e., difficulty in breathing or coughing which may be linked to infections you have caught as a result of your disease; if you have previously had skin reactions, i.e., pain, redness and dryness of skin, during treatment with radiotherapy, this may also happen with Caelyx; joint pain, decreased or abnormal sensation to stimulation, inflammation of the cornea, redness of the eye, redness of the scrotum may occur with a combination of Caelyx and bortezomib.
Če ste že imeli kožne reakcije, npr. bolečine, pordelo in suho kožo med obsevanjem (radioterapijo), se lahko te med zdravljenjem z zdravilom Cealyx ponovijo. bolečine v sklepih, zmanjšan ali nenormalen občutek pri stimulaciji, vnetje roženice, pordelost očesa, pordelost mošnje pri moškem, ki se lahko pojavi pri jemanju zdravila Caelyx v kombinaciji z bortezomibom.